Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Heidelberg Pharma AG

www.heidelberg-pharma.com

Latest From Heidelberg Pharma AG

Appointments: New CEO For Silence Therapeutics, Medical Heads Join Merck, Breath Therapeutics, Immusoft

David Solomon’s entrance as Silence Therapeutics’ new CEO leads this week’s new hires. While Ireland-based Malin shakes up its board of directors, other execs join Merck, Apeiron Biologics, Vectura, Roivant, OncoSec, Breath Therapeutics, Immusoft and M3 Biotechnology.

Appointments BioPharmaceutical

Start-Up Quarterly Statistics: Early Funding Declined, But Deal Dollars Flowed

A review of biopharma startup dealmaking and financing activity from January through March 2017, based on data from Strategic Transactions, showed a 19% decline in startup financing compared with the fourth quarter of 2016, but big pharmas provided capital in the form of alliance fees.

StartUps and SMEs Financing

Deal Watch: Genentech Pays Big For Seragon’s Early Assets

Genentech pays $725 million upfront for San Diego oncology firm Seragon, and Bluebird adds gene-editing and cell-signaling capabilities by acquiring Precision Genomic Engineering. It was a deal-heavy week ahead of the July 4th Holiday.

BioPharmaceutical Deals

BioNotebook: PaxVax, Bluebird/Pregenen, RedHill/Wilex, CureVac/Sanofi Pasteur, Synchroneuron, Advanced Cell, Raptor, Ablynx

PaxVax has 1st Phase III success; Bluebird buys Pregenen; RedHill acquires Wilex asset; Sanofi options CureVac vaccine; Synchroneuron gets VC funding; and Advanced Cell, Raptor, Ablynx raise new cash.

Gastrointestinal Infectious Diseases
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Radiopharmaceuticals, Contrast Agents
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Wilex Biotechnology GMBH
  • Wilex AG
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Germany
  • Parent & Subsidiaries
  • Heidelberg Pharma AG
  • Senior Management
  • Jan Schmidt-Brand, PhD, CEO & CFO
    Andreas Pahl, Head, R&D
  • Contact Info
  • Heidelberg Pharma AG
    Phone: (49) 6203 1009 0
    Schriesheimer Str. 101
    Ladenburg, D-68526
    Germany
Advertisement
Advertisement
UsernamePublicRestriction

Register